Adicet Bio Inc (ACET)

$0.71 -0.01 (-1.94%)
Market Cap 60.53M
Revenue (ttm) 0.00
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 411,097
Avg Vol 512,602
Day's Range N/A - N/A
Shares Out 83.25M
Stochastic %K 85%
Beta 1.59
Analysts Strong Sell
Price Target $6.00

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 503 9095
Address:
131 Dartmouth Street, 3rd Floor, Boston, United States
TWITLIEDETECTOR
TWITLIEDETECTOR Aug. 23 at 11:06 PM
$ACET don’t chase price
0 · Reply
ZoneDash
ZoneDash Aug. 23 at 4:34 AM
$ACET Adicet Bio is a clinical-stage immuno-oncology company developing cell therapies with high cash burn
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 8:43 PM
$OPEN trimmed profits here. Into $CGTX. Our members knew about Open and CGTX days ago. Started a light position in $MERC among others. Sign up for alerts and be in time for the party instead of finding them because they jumped up. The trade commando system is consistently nailing tickers days before they move. It's time to get into $ACET, I suppose! Have a great weekend
0 · Reply
UnicornChaser
UnicornChaser Aug. 22 at 2:31 PM
$ACET nice to see all the volume this week. Gaining some traction! 💪
0 · Reply
King_of_Bio
King_of_Bio Aug. 22 at 2:19 PM
$ACET Nice to see some action here finally!
0 · Reply
tr1llA
tr1llA Aug. 22 at 1:58 PM
$ACET bought some $2.5 calls expiring in January for 0.10 just because
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 22 at 10:07 AM
$ACET making changes off this 0.67*
0 · Reply
CCat07
CCat07 Aug. 21 at 8:07 PM
$ACET almost 3x average volume today.. someone know something?
0 · Reply
Kevin_Gough
Kevin_Gough Aug. 21 at 7:46 PM
$ACET We have a little PH volume coming in!!! First time in a while for some buying volume!!!
0 · Reply
TwinTrades
TwinTrades Aug. 21 at 7:35 PM
$ACET Potential breakout in the cards…
1 · Reply
Latest News on ACET
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 4:01 PM EDT - 17 days ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Aug 5, 2025, 7:00 AM EDT - 20 days ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Jul 24, 2025, 7:00 AM EDT - 4 weeks ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:00 PM EDT - 3 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:01 PM EDT - 3 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2025, 4:47 PM EDT - 4 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Apr 17, 2025, 7:00 AM EDT - 4 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 5:12 PM EDT - 5 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 4:01 PM EST - 6 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Mar 3, 2025, 7:00 AM EST - 6 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 27, 2025, 7:00 AM EST - 6 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Feb 5, 2025, 7:10 AM EST - 7 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:00 AM EST - 7 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Jan 8, 2025, 4:10 PM EST - 8 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2024, 4:48 PM EST - 8 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 19, 2024, 7:00 AM EST - 8 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dec 18, 2024, 7:00 AM EST - 8 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 4:00 PM EST - 9 months ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 18, 2024, 7:00 AM EST - 10 months ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 16, 2024, 9:00 AM EST - 10 months ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:00 PM EST - 10 months ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 5, 2024, 7:00 AM EST - 10 months ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 10 months ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Oct 16, 2024, 7:00 AM EDT - 11 months ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 4:30 PM EDT - 11 months ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jan 25, 2024, 4:01 PM EST - 1 year ago

Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Adicet Bio, Inc. Announces Pricing of Public Offering

Jan 22, 2024, 11:43 PM EST - 1 year ago

Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering

Jan 22, 2024, 4:28 PM EST - 1 year ago

Adicet Bio, Inc. Announces Proposed Public Offering

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Jan 8, 2024, 7:19 PM EST - 1 year ago

Adicet Bio: Clinical Updates In 2H 2024 Makes This A Must-Watch

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Jan 4, 2024, 7:00 AM EST - 1 year ago

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Jan 3, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

TWITLIEDETECTOR
TWITLIEDETECTOR Aug. 23 at 11:06 PM
$ACET don’t chase price
0 · Reply
ZoneDash
ZoneDash Aug. 23 at 4:34 AM
$ACET Adicet Bio is a clinical-stage immuno-oncology company developing cell therapies with high cash burn
0 · Reply
mhaven2020
mhaven2020 Aug. 22 at 8:43 PM
$OPEN trimmed profits here. Into $CGTX. Our members knew about Open and CGTX days ago. Started a light position in $MERC among others. Sign up for alerts and be in time for the party instead of finding them because they jumped up. The trade commando system is consistently nailing tickers days before they move. It's time to get into $ACET, I suppose! Have a great weekend
0 · Reply
UnicornChaser
UnicornChaser Aug. 22 at 2:31 PM
$ACET nice to see all the volume this week. Gaining some traction! 💪
0 · Reply
King_of_Bio
King_of_Bio Aug. 22 at 2:19 PM
$ACET Nice to see some action here finally!
0 · Reply
tr1llA
tr1llA Aug. 22 at 1:58 PM
$ACET bought some $2.5 calls expiring in January for 0.10 just because
0 · Reply
Love_To_Learn
Love_To_Learn Aug. 22 at 10:07 AM
$ACET making changes off this 0.67*
0 · Reply
CCat07
CCat07 Aug. 21 at 8:07 PM
$ACET almost 3x average volume today.. someone know something?
0 · Reply
Kevin_Gough
Kevin_Gough Aug. 21 at 7:46 PM
$ACET We have a little PH volume coming in!!! First time in a while for some buying volume!!!
0 · Reply
TwinTrades
TwinTrades Aug. 21 at 7:35 PM
$ACET Potential breakout in the cards…
1 · Reply
buymoremakemore
buymoremakemore Aug. 21 at 6:35 PM
$ACET An off the shelf Car T Cell Therapy company focused on B cell malignancies got bought out for 350M today. We are also off the shelf, and focus on b cell depletion for both autoimmune and oncology. If phase 1 data readout(s) are good it could be our turn!!! https://seekingalpha.com/news/4487922-gilead-kite-buying-interius-biotherapeutics-350m
1 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 21 at 5:13 PM
This $ACET is undervalued.
0 · Reply
MGeronimo
MGeronimo Aug. 21 at 4:35 PM
$ACET accumulating at .67
0 · Reply
AGC_Trader
AGC_Trader Aug. 21 at 1:30 PM
$ACET The price action has been really weird these past days, I guess something is brewing
0 · Reply
TwinTrades
TwinTrades Aug. 20 at 11:45 PM
$ACET Closing strong. Good day tomorrow in the cards.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 19 at 9:13 PM
$ACET ah movers...
0 · Reply
TheInvestorWithNoName
TheInvestorWithNoName Aug. 19 at 3:36 PM
$ACET When are we expecting next test results?
2 · Reply
mhaven2020
mhaven2020 Aug. 19 at 2:32 PM
$ACET hey there. Is there a party here week?
0 · Reply
Welcome548
Welcome548 Aug. 19 at 1:29 PM
$ACET it's alive and ready for a news release and pop in price. Jmho $10 near future! 🚀🚀🚀🚀
1 · Reply
Welcome548
Welcome548 Aug. 19 at 1:29 PM
$ACET
0 · Reply
NEWBIGTECH
NEWBIGTECH Aug. 18 at 8:53 PM
$ACET undervalued. Gem.
0 · Reply
Welcome548
Welcome548 Aug. 18 at 7:53 PM
$ACET news coming soon jmho
0 · Reply